for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

AbbVie Inc

ABBV.N

Latest Trade

76.46USD

Change

1.32(+1.76%)

Volume

2,435,495

Today's Range

75.24

 - 

77.17

52 Week Range

62.68

 - 

94.98

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
75.14
Open
75.24
Volume
2,435,495
3M AVG Volume
181.45
Today's High
77.17
Today's Low
75.24
52 Week High
94.98
52 Week Low
62.68
Shares Out (MIL)
1,478.78
Market Cap (MIL)
113,067.70
Forward P/E
8.59
Dividend (Yield %)
5.60

Next Event

Q3 2019 AbbVie Inc Earnings Release

Latest Developments

More

AbbVie Receives CHMP Positive Opinion For Upadacitinib (RINVOQ) For Treatment Of Adults With Moderate To Severe Active Rheumatoid Arthritis

Allergan Shareholders Approve Proposed Acquisition By Abbvie

Reata Pharmaceuticals Reacquires Rights From Abbvie To Develop And Commercialize Bardoxolone Methyl, Omaveloxolone, And All Next-Generation Nrf2 Activators

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About AbbVie Inc

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).

Industry

Biotechnology & Drugs

Contact Info

1 N Waukegan Rd

+1.847.9327900

https://www.abbvie.com/

Executive Leadership

Richard A. Gonzalez

Chairman of the Board, Chief Executive Officer

Michael E. Severino

President, Vice Chairman

Carlos Alban

Vice Chairman, Chief Commercial Officer

Laura J. Schumacher

Vice Chairman, External Affairs and Chief Legal Officer

Robert A. Michael

Chief Financial Officer, Senior Vice President

Key Stats

2.09 mean rating - 11 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

25.6K

2017

28.2K

2018

32.7K

2019(E)

33.2K
EPS (USD)

2016

4.820

2017

5.600

2018

7.910

2019(E)

8.903
Price To Earnings (TTM)
27.55
Price To Sales (TTM)
3.47
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
18.56
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
9.94
Return on Equity (TTM)
7.08

Latest News

Latest News

FTC requests AbbVie, Allergan for more information on $63 billion deal

The U.S. Federal Trade Commission (FTC) has requested for more information from AbbVie Inc <ABBV.N> and botox maker Allergan Plc <AGN.N> on their $63 billion deal, the companies said on Friday.

Consumer groups, unions urge caution on $63 billion AbbVie deal for Allergan

About a dozen advocacy groups and unions, including Public Citizen and the American Federation of Teachers, wrote the Federal Trade Commission on Thursday urging it to consider blocking drugmaker AbbVie Inc's <ABBV.N> planned $63 billion purchase of Botox maker Allergan...

AbbVie abandons late-stage lung cancer asset Rova-T

AbbVie Inc said on Thursday it will cease to develop its experimental drug Rova-T after the treatment failed to show survival benefit in a late-stage trial for a type of lung cancer. The drugmaker acquired Rova-T through its $5.8 billion acquisition of Stemcentrx in 2016...

AbbVie terminates late-stage lung cancer trial

AbbVie Inc on Thursday said it will discontinue the late-stage trial testing its experimental treatment for a type of lung cancer after it failed to show a survival benefit compared to placebo.

FDA flags risks from AbbVie, Gilead, Merck hepatitis C drugs to certain patients

The U.S. Food and Drug Administration said on Wednesday it had identified 63 cases of worsening liver function in certain patients taking hepatitis C medicines made by drugmakers Merck & Co Inc, Gilead Sciences and AbbVie Inc.

FDA flags serious risks with hepatitis C drugs from AbbVie, Gilead and Merck

The U.S. Food and Drug Administration said on Wednesday it had identified 63 cases of worsening liver function in certain patients taking hepatitis C medicines made by drugmakers Merck & Co Inc, Gilead Sciences and AbbVie Inc.

AbbVie prices new rheumatoid arthritis drug at $59,000 a year

AbbVie Inc has priced its new rheumatoid arthritis treatment at $59,000 a year after gaining U.S. approval on Friday, a big boost for the drugmaker struggling with rising competition for Humira, its blockbuster therapy for the same condition.

FDA approves AbbVie's new rheumatoid arthritis drug

The U.S. Food and Drug Administration on Friday approved AbbVie Inc's new treatment for rheumatoid arthritis, a win for the drugmaker seeking to widen its portfolio as its blockbuster flagship therapy Humira faces competition.

Allergan beats profit, raises revenue forecast on Restasis, Juvederm demand

Allergan Plc <AGN.N>, which is being bought by AbbVie Inc <ABBV.N> for $63 billion, beat quarterly profit estimates and raised its 2019 revenue forecast on Tuesday, helped by demand for its dry eye drug Restasis and aesthetics product Juvederm.

AbbVie spotlights Allergan deal, new drugs as Humira sales wane

AbbVie Inc <ABBV.N> said on Friday a combination of new drugs in its arsenal and its planned $63 billion deal for Botox-maker Allergan Plc <AGN.N> will counter declining sales of its long-time bestseller, Humira.

AbbVie does not expect to divest new psoriasis drug

AbbVie Inc <ABBV.N> said on Friday it does not expect the Federal Trade Commission would require divestiture of its recently approved psoriasis drug Skyrizi in connection with the company's $63 billion pending deal to buy Allergan Plc <AGN.N>.

AbbVie does not expect to divest new psoriasis drug

AbbVie Inc said on Friday it does not expect the Federal Trade Commission would require divestiture of its recently approved psoriasis drug Skyrizi in connection with the company's $63 billion pending deal to buy Allergan Plc.

AbbVie raises 2019 profit target as quarterly sales beat estimates

Drugmaker AbbVie Inc on Friday raised its earnings forecast for the year and beat Wall Street estimates for second-quarter revenue, as sales of its top-selling drug Humira did not fall as much as analysts had feared.

Samsung Bioepis Humira biosimilar wins FDA approval

(This story corrects to show that Hadlima belongs to Samsung Bioepis not Merck & Co Inc, which is commercializing the drug in the United States)

CORRECTED-US loan market ready to feast on AbbVie's jumbo US$38bn bridge loan

A US$38bn bridge loan backing US biopharmaceutical company AbbVie’s US$63bn bid for Botox-maker Allergan, and the additional bank business the merger will generate, is expected to be welcomed with open arms by a robust US loan market starved of new lending opportunities.

AbbVie looks beyond Humira with $63 billion deal for Botox-maker Allergan

Drugmaker AbbVie Inc said on Tuesday it would acquire Allergan Plc for about $63 billion (£49.6 billion), giving AbbVie control over the lucrative wrinkle treatment Botox and buying time to seek new growth before its blockbuster arthritis treatment Humira loses U.S. patent...

Deals of the day-Mergers and acquisitions

The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Tuesday:

US STOCKS-Wall St sinks on trade jitters ahead of Powell speech

* Indexes down: 0.15%, S&P 0.32%, Nasdaq 0.61% (Updates to mid-day, changes dateline, byline)

US STOCKS-Wall St dragged down by Iran tensions, trade worries; Fed in focus

* Indexes down: 0.21%, S&P 0.41%, Nasdaq 0.75% (Changes comment, adds details, updates prices)

AbbVie nears deal to buy Allergan for more than $60 bln - WSJ

AbbVie Inc is nearing a deal to buy Botox-maker Allergan PLC for more than $60 billion, the Wall Street Journal reported on Tuesday, citing people familiar with the matter.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up